JP2005529954A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529954A5
JP2005529954A5 JP2004513249A JP2004513249A JP2005529954A5 JP 2005529954 A5 JP2005529954 A5 JP 2005529954A5 JP 2004513249 A JP2004513249 A JP 2004513249A JP 2004513249 A JP2004513249 A JP 2004513249A JP 2005529954 A5 JP2005529954 A5 JP 2005529954A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
following formula
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004513249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529954A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/019211 external-priority patent/WO2003106416A2/en
Publication of JP2005529954A publication Critical patent/JP2005529954A/ja
Publication of JP2005529954A5 publication Critical patent/JP2005529954A5/ja
Pending legal-status Critical Current

Links

JP2004513249A 2002-06-17 2003-06-17 化学プロセス Pending JP2005529954A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38934902P 2002-06-17 2002-06-17
PCT/US2003/019211 WO2003106416A2 (en) 2002-06-17 2003-06-17 Chemical process

Publications (2)

Publication Number Publication Date
JP2005529954A JP2005529954A (ja) 2005-10-06
JP2005529954A5 true JP2005529954A5 (enExample) 2006-08-03

Family

ID=29736629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004513249A Pending JP2005529954A (ja) 2002-06-17 2003-06-17 化学プロセス

Country Status (10)

Country Link
US (1) US20060252943A1 (enExample)
EP (1) EP1515955A4 (enExample)
JP (1) JP2005529954A (enExample)
CN (1) CN1688553A (enExample)
AU (1) AU2003276125B2 (enExample)
CA (1) CA2489648A1 (enExample)
IL (1) IL165286A0 (enExample)
MX (1) MXPA04012860A (enExample)
PL (1) PL374963A1 (enExample)
WO (1) WO2003106416A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
KR20050122220A (ko) 2003-03-25 2005-12-28 다케다 샌디에고, 인코포레이티드 디펩티딜 펩티다제 억제제
HRP20130602T1 (en) 2003-07-30 2013-07-31 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8003744B2 (en) 2003-08-25 2011-08-23 Kaneka Corporation Curing composition with improved heat resistance
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
WO2006020564A1 (en) * 2004-08-09 2006-02-23 Smithkline Beecham Corporation Pyrimidin derivatives for the treatment of multiple myeloma
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CA2608367C (en) 2005-06-08 2014-08-19 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
SI1954281T1 (sl) 2005-11-29 2011-06-30 Glaxosmithkline Llc Postopek zdravljenja raka
JP5180834B2 (ja) 2005-11-29 2013-04-10 スミスクライン ビーチャム コーポレーション 治療方法
ES2622493T3 (es) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DK2154967T5 (en) 2007-04-16 2014-11-17 Hutchison Medipharma Entpr Ltd Pyriminderivater
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
KR20100132550A (ko) 2008-04-16 2010-12-17 포톨라 파마슈티컬스, 인코포레이티드 syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US20120232102A1 (en) 2009-09-30 2012-09-13 Chun-Fang Xu Methods Of Administration And Treatment
US20120197019A1 (en) * 2009-10-23 2012-08-02 Dharmesh Surendra Bhanushali Compositions and processes
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
CA2816219C (en) 2010-11-01 2019-10-29 Portola Pharmaceuticals, Inc. Nicotinamides as syk modulators
EP2635557A2 (en) 2010-11-01 2013-09-11 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
CA2819118A1 (en) * 2010-11-29 2012-06-07 Hetero Research Foundation A process for the preparation of pazopanib using novel intermediate
CN102060848B (zh) * 2010-12-09 2013-09-18 天津药物研究院 芳香胺取代的嘧啶衍生物的制备及用途
SG10201601352UA (en) 2011-11-23 2016-03-30 Portola Pharm Inc Pyrazine kinase inhibitors
CN103319410B (zh) * 2012-03-22 2016-04-06 天津药物研究院 一种吲唑化合物的合成方法
CN103373989B (zh) * 2012-04-28 2016-04-13 上海医药工业研究院 盐酸帕唑帕尼的中间体的制备方法
CN103373963B (zh) * 2012-04-28 2015-07-08 上海医药工业研究院 盐酸帕唑帕尼的中间体及其制备方法
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
EP2935250B1 (en) 2012-12-17 2018-03-28 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
WO2014097152A1 (en) * 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
CN103232443B (zh) * 2013-02-01 2014-12-10 天津药物研究院 一种吲唑衍生物的晶型及其制备和用途
CN103450085B (zh) * 2013-08-15 2015-11-18 凯莱英医药集团(天津)股份有限公司 一种盐酸帕唑帕尼关键中间体的制备方法
WO2015068175A2 (en) * 2013-11-05 2015-05-14 Laurus Labs Private Limited An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN106565688B (zh) * 2016-11-11 2018-08-31 重庆医科大学 帕唑帕尼二聚体及其制备方法和用途
CN110028495B (zh) * 2019-05-24 2019-12-03 济南爱思医药科技有限公司 帕唑帕尼盐酸盐的制备方法
CN116554106A (zh) * 2023-04-28 2023-08-08 扬州市普林斯医药科技有限公司 一种6-氯-2-甲基-2h-吲唑-5-胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
JP2003532635A (ja) * 2000-02-17 2003-11-05 アムジエン・インコーポレーテツド キナーゼ阻害薬
JP3711443B2 (ja) * 2000-10-25 2005-11-02 セイコーエプソン株式会社 インクジェット式記録装置
IL156306A0 (en) * 2000-12-21 2004-01-04 Glaxo Group Ltd Pyrimidineamines as angiogenesis modulators
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2005529954A5 (enExample)
JP2007500753A5 (enExample)
US8946416B2 (en) Process for the synthesis of 5-(methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzeneamine
JP2002534519A5 (enExample)
JP2007518682A5 (enExample)
JP2009515872A5 (enExample)
JP2006519232A5 (enExample)
PE20010031A1 (es) Azoles sustituidos como inhibidores de la produccion de tnf
ATE458483T1 (de) Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
JP2012510502A5 (enExample)
JP2003267957A5 (enExample)
JP2005502658A5 (enExample)
JP2005535586A5 (enExample)
JP2004502690A5 (enExample)
JP2004532240A5 (enExample)
JP2007510619A5 (enExample)
JP2004528385A5 (enExample)
JP2004508309A5 (enExample)
JP2009184932A5 (enExample)
JP2006515600A5 (enExample)
JP2005514512A5 (enExample)
JP2007533735A5 (enExample)
JP2005508292A5 (enExample)
EP1302467A3 (de) Verfahren zur Herstellung von substituierten Thiazolinen und deren Zwischenprodukte
JP2007506665A5 (enExample)